Expanding Horizons: Antibody Drug Conjugates in Non-Small Cell Lung Cancer - Episode 2

ADCs in Development for the Treatment of Lung Cancer

,

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Antibody Drug Conjugates in Lung Cancer
    Now Viewing
    EP. 2: ADCs in Development for the Treatment of Lung Cancer
    EP. 3: Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer
    EP. 4: HER2-Directed Agents in NSCLC
    EP. 5: Targeting HER3 in EGFR-Mutant NSCLC
    EP. 6: Exploring TROP2 Expression in Patients with NSCLC
    x